High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction (HIT-HF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03184311|
Recruitment Status : Not yet recruiting
First Posted : June 12, 2017
Last Update Posted : July 9, 2019
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure With Normal Ejection Fraction||Other: High-intensity interval training (HIT) Other: Moderate-intensity contiuous training (MCT)||Not Applicable|
Heart failure (HF) with preserved ejection fraction (HFpEF) occurs in about 50% of all HF patients. Remodeling and fibrosis stimulated by inflammation appear to be main factors for the progression of HFpEF. The lack of prognostic treatment options in HFpEF urgently calls for new therapeutic approaches. While beneficial effects of exercise training have been demonstrated in HF with reduced ejection fraction, they have not yet been evaluated in HFpEF. Therefore, the aim of this study is to investigate the effects of high-intensity interval training (HIT) in HFpEF patients.
The proposed study will be a prospective, single-blind, randomized controlled trial in a primary care setting including 86 patients with stable HFpEF. Patients will undergo 3 study visits (a screening visit, a baseline visit and a post-intervention visit) including measurements of disease-specific biomarkers (using blood samples), cardiac and arterial vessel structure and function (using electrocardiogram, echocardiography and pulse wave velocity), exercise tolerance (using spiroergometry), habitual physical activity (using accelerometry) and QoL. After the baseline visit, patients will be randomized to either the intervention or control group. The intervention group (n=43) will attend a supervised 12-week HIT on a bicycle ergometer, while the control group (n=43) will attend a supervised 12-week moderate-intensity continuous training (MCT). After 12 weeks, the study measurements will be repeated in all patients (intervention and control group) in order to monitor the effects of the intervention (post-intervention visit). At 6 months, 1, 2 and 3 years after the last study visit, telephone interviews will be performed to assess medical outcomes and QoL.
Outlook: This study is expected to add important knowledge about the potential utility of a novel treatment strategy in HFpEF patients, which may help to improve both, QoL and functional status. Moreover, the analysed biomarkers might be able to provide further insight into prognosis and pathogenesis of HFpEF.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||86 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||Study personnel involved in the study measurements will be blinded to whether patients are allocated to the intervention or control group. Furthermore, the statistician will be blinded to treatment allocation. To ensure blinding, the study measurements will be performed in different rooms and by different staff than those involved in the training intervention. It is not possible to blind participating patients and investigators performing the randomization and training sessions.|
|Official Title:||High-intensity Interval Training as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction: A Prospective, Single-blind, Randomized Controlled Trial|
|Estimated Study Start Date :||July 2019|
|Estimated Primary Completion Date :||July 2022|
|Estimated Study Completion Date :||December 2022|
Experimental: High-intensity interval training (HIT)
A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
Other: High-intensity interval training (HIT)
Supervised 12-week HIT 3 times per week on a bicycle ergometer.
Placebo Comparator: Moderate-intensity continuous training (MCT)
A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
Other: Moderate-intensity contiuous training (MCT)
Supervised 12-week MCT 3 times per week on a bicycle ergometer.
- Change in peak oxygen uptake (VO2peak) due to training [ Time Frame: Baseline and 12 weeks ]VO2peak will be measured by spiroergometry at the baseline and post-intervention visit: an incremental symptom-limited exercise test on an electronically operated bicycle ergometer (eBike, General Electric Company, Fairfield, Connecticut, USA) using a fixed ramp protocol (start at 10 watts, increase of 10 watts/minute) will be conducted. The test will be performed in an air-conditioned laboratory in the early afternoon under non-fasting conditions. After a 2-minute warm-up at 10 watts, patients will be instructed to pedal at a constant rate of 60 rpm to exhaustion or until signs of ischemia or serious cardiac arrhythmias appear. The exercise bout will be followed by a cool-down at 25 watts for 10 minutes or until HR is dropping down below 100 beats/minute. VO2peak will be defined as the highest value reached during exercise.
- Change in disease-specific biomarkers [ Time Frame: Baseline and 12 weeks ]For measuring N-terminal prohormone of brain natriuretic peptide (NT-proBNP), Renin, Angiotensin-II (AT-2), Urocortin-2 (UCN-2), Osteopontin, Soluble ST2 (sST2), Galectin-3, Growth differentiation factor 15 (GDF-15), Copeptin, Big-Endothelin-1, Placental growth factor/Soluble Fms-like tyrosine-kinase 1 (PlGF/sFlt-1), High-sensitivity C-reactive protein (Hs-CRP), Interleukin 6 (IL-6) and Insulin-like growth factor-binding protein 7 (IGF-BP7), blood samples will be taken (in total 40 ml of blood) and immediately centrifuged, and the serum will be transferred to a separate tube, which will be frozen at approximately -80°C and stored in the central laboratory at the Cantonal Hospital Baselland in Liestal until the last patient will have completed the study procedures.
- Change in echocardiographic parameters of the left ventricular systolic and diastolic function [ Time Frame: Baseline and 12 weeks ]An echocardiography will be performed using a Full HD Color Doppler Ultrasound Scanner UF-890AG (Fukuda Denshi, Tokyo, Japan) by experienced echocardiographers blinded to the assignment of the patient to the intervention or control group, and independently analysed by cardiologists of the KSBL Liestal.
- Change in arteriovenous oxygen difference (Da-vO2) [ Time Frame: Baseline and 12 weeks ]Da-vO2 will be calculated using the Fick Principle: Peak Da-vO2 = VO2peak / peak cardiac output. VO2peak will be measured by spiroergometry, while peak cardiac output will be determined using the Full HD Color Doppler Ultrasound Scanner UF-890AG (Fukuda Denshi, Tokyo, Japan).
- Change in pulse wave velocity (PWV) [ Time Frame: Baseline and 12 weeks ]PWV will be measured at the same time as the echocardiographic parameters with the VaSera VS-2000 Vascular Screening System (Fukuda Denshi Co. Ltd, Tokyo, Japan) and evaluated by experienced blinded members of the study team.
- Change in daily physical activity [ Time Frame: Baseline and 12 weeks ]The number of daily steps, physical activity level and time spent at different walking speeds will be measured by the AiperMotion 440 PC (Aipermon GmbH, Munich, Germany), a three-axis accelerometer that is attached to the belt on the left hip, on 7 consecutive days for at least 12 hours a day with the exception of the time spent for showering, bathing and sleeping. For recording daily activities and non-wearing periods, patients will be asked to keep a diary.
- Change in NYHA functional class [ Time Frame: Baseline and 12 weeks ]NYHA functional class will be determined according to the New York Heart Association classification.
- Change in quality of life (QoL): The 36-Item Short Form Health Survey (SF-36) [ Time Frame: Baseline and 12 weeks ]The SF-36 consists of 36 items, which are formatted as binary questions or as semantic 6-point differential scales. It refers to the past 4 weeks and includes 9 content areas concerning vitality, general health perception, physical functioning, social functioning, role limitations (emotional/physical problems), pain, mental health and health change.
- Change QoL: The Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Baseline and 12 weeks ]The KCCQ consists of 15 items concerning overall symptoms, emotional, social and mental status within the past 2 weeks.
- Change in QoL: The Minnesota Living With Heart Failure Questionnaire (MLWHFQ) [ Time Frame: Baseline and 12 weeks ]The MLWHFQ refers to the past 4 weeks and includes 21 questions on a 6-point scale with a maximum of 105 points (<24 good QoL, >45 poor QoL).
- Change in body composition: Body Mass Index (BMI) [ Time Frame: Baseline and 12 weeks ]BMI will be calculated from measured height in meters and weight in kilograms. Weight and height will be combined to report BMI in kg/m^2.
- Change in body composition: Waist-to-Hip-Ratio (WHR) [ Time Frame: Baseline and 12 weeks ]WHR will be calculated from measured waist circumference (WC) and hip circumference (HC) in centimetres. WC will be divided by HC to report WHR.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03184311
|Contact: Thomas Dieterle, MD||+41 61 925 32 email@example.com|
|Contact: Maria Bösing, MMed||+41 61 925 37 firstname.lastname@example.org|
|Principal Investigator:||Thomas Dieterle, MD||University Department of Internal Medicine, Cantonal Hospital Baselland|